Tissue factor pathway inhibitor antigen and activity in 96 patients receiving heparin for cardiopulmonary bypass

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 16, Issue 1, 2002, Pages 59-63

  Adams, Murray J ^a   Cardigan, Rebecca A ^a   Marchant, Warwick A ^a   Grocott, Michael P W ^a   Mythen, Monty G ^a   Mutch, Maj ^a   Purdy, Gordon ^a   Mackie, Ian J ^a   Machin, Samuel J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiopulmonary bypass; Heparin; Thrombosis; Tissue factor pathway inhibitor (TFPI)

Indexed keywords

HEPARIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; CONTROLLED STUDY; FEMALE; HEART SURGERY; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS;

EID: 0036168004     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/jcan.2002.29677     Document Type: Article

References (21)

1. Studies of a mechanism inhibiting the initiation of the extrinsic pathway of coagulation
2. Characterisation of the inhibition of tissue factor in serum
3. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
4. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-stop model of inhibition
5. Heparin induces release of extrinsic pathway coagulation inhibitor (EPI)
6. Inhibition of the tissue factor-factor VII complex: Involvement of factor Xa and lipoproteins
7. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor
8. The present status of tissue factor pathway inhibitor
9. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant
10. Consequences of tissue factor pathway inhibitor gene-disruption in mice
11. Haemostatic changes in the pulmonary blood during cardiopulmonary bypass
12. A sensitive assay of extrinsic pathway inhibitor (EPI) in plasma and plasma fractions
13. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis
14. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass
15. Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
16. Low levels of tissue factor pathway inhibitor (TFPI) in two out of three members of a family with thrombophilia
17. Measurement of tissue factor pathway inhibitor in normal and post-heparin plasma
18. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor
19. Measurement of functional and immunologic levels of tissue factor pathway inhibitor: Some methodologic considerations
20. Lipoprotein(a) changes during and after coronary artery bypass grafting: An epiphenomenon?
21. Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery